Dr. John Cush RheumNow
2 years 8 months ago
Pneumocystis Jiroveci Pneumonia (PJP) Risk
https://t.co/6kP3IjmHi1 https://t.co/ERwIeTKBYp
Since the millennium, we have seen an expansion in the number of advanced treatments both biologic and targeted synthetic disease modifying anti-rheumatic drugs for rheumatoid arthritis. The challenge remains on how best to characterise the subtypes of RA in order to choose the best drug to ensure optimal outcome for patients.
A recent New England Journal review of post-menopausal osteoporosis (OP) provided updated information, strategies and a review of guidelines and clinical recommendations. Here are the salient highlights.
Few people are aware of the EULAR recommendations for cardiovascular risk management in SLE published in 2022. The recommendations had 4 overarching principles: increase awareness of elevated cardiovascular risk, need for regular cardiovascular screening, assess and manage modifiable risk factors, and patient education. During ACR 2023 Convergence, several abstracts were presented evaluating the prevalence of CV disease and exploring new
Dr. John Cush RheumNow
2 years 8 months ago
resolved HBV (HBsAg-, HBcAb+, HBsAb+) are at low risk of reactivation (~2%) w/ TNFi or biologics. But in a high risk endemic region (ie, Korea) this risk is higher. Study of 416 such pts HBV reactivation rate 3.5% @5 yrs, 6.1% @10 yrs & 24.2% @17 yrs https://t.co/oQ5e6O9wds https://t.co/50vBtapJVN
Dr. John Cush RheumNow
2 years 8 months ago
Risk of Hepatitis B reactivation is assessed by serology
- Resolved HBV (low risk reactiv): HBsAg-neg, HBcAb–pos & Pos HBsAb
- If HBcAb(+), HBsAb negativity incr risk;
- HBsAg(-), HBcAb(+), HBsAb(-) negative= resolved infx, occult infx, chronic hepatitis
https://t.co/91ZwqWkdvo https://t.co/c23nN8ER1Y
Dr. John Cush RheumNow
2 years 8 months ago
#RA pattern of synovitis is well knownn & decr in grip strength seen in Early (39%) & later RA (59% @5y). MCP1 synovitis impacts grip strength most (60%) followed by MCP4 (much less w/ tender/swelling of PIPs,other MCPs). Based on study of 215 early RA pts https://t.co/rTFBHKlNGV https://t.co/zCVsTNuYWW
Dr. John Cush RheumNow
2 years 8 months ago
ARCTIC Rewind: Three-Year Data in RA
https://t.co/ls2e3LtlvK https://t.co/FtgSq713rc
Dr. John Cush RheumNow
2 years 8 months ago
Rheum Fellowship Slots Fill Up for 2024
The NRMP announced yesterday that the 2024 rheumatology fellowship match filled 97.6% (124/127) of programs, and 98.9% (273/276) of rheumatology fellowship positions.
https://t.co/wTwajHyal0 https://t.co/JpgDUmioQh
Dr. John Cush RheumNow
2 years 8 months ago
Early bird pricing has been extended! Register today!
https://t.co/wuvDqE0Qe6 https://t.co/8XXcQUBK6G https://t.co/ISRYMVdRfr
Dr. John Cush RheumNow
2 years 8 months ago
What do you think of the concept of "dysuricemia" - the concept that both hyperuricemia and hypouricemia influence diseases. “The lower, the better” is incorrect; the ideal is to maintain normouricemia, or optimal SU level, to reduce the urate burden https://t.co/vYSNzWuPVW https://t.co/tde3Mh6Wij
Dr. John Cush RheumNow
2 years 8 months ago
Do We Stop or Continue Treatment?
Remission had been a dream, an elusive concept. But then, with the introduction of biologics, conventional synthetic and targeted synthetic DMARDS, patients are able to live longer and with a better quality of life.
https://t.co/2ecihSwGIV https://t.co/rAjHvlyMB8
Dr. John Cush RheumNow
2 years 8 months ago
WATCH: TMP SMX Prophylaxis in GPA
https://t.co/VEkGFUewjG https://t.co/HouepsLEuw https://t.co/r1kiXejFQn

